Avid Bioservices Inc (CDMO)

[entdoc]

all off the top of my head...DNDN was pushing 20 when it crashed to less than 5 because it had not established statistically significance. Huge setback. Exactly the same order of magnitude setback as PPHM's September 2012 fiasco. But I do not remember that Provenge was in anyway subverted. Its numbers simply were not good enough to overwhelm the FDA. What the Provenge trial numbers did not do, public support did, and Provenge was revived, but barely, as the previous article attests. In the case of PPHM and Bavituximab (which is only one of a number of PPHM pipeline winners), this is only the first of an enormous number of spinoffs possible by adding the simplest chemical tweak. A cinch.